<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Fluconazole</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00196</strong>&#160; (APRD00327)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Triazole antifungal agent that is used to treat oropharyngeal candidiasis and cryptococcal meningitis in <span class="caps">AIDS</span>. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00196/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00196/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00196.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00196.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00196.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00196.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00196.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00196">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Diflucan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Elazor</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Flucazol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Flucostat</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Flunizol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Monicure</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pritenzol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Trican</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Triflucan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antifungal-agents">Antifungal Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>86386-73-4</td></tr><tr><th>Weight</th><td>Average: 306.2708<br>Monoisotopic: 306.104065446</td></tr><tr><th>Chemical Formula</th><td>C<sub>13</sub>H<sub>12</sub>F<sub>2</sub>N<sub>6</sub>O</td></tr><tr><th>InChI Key</th><td>RFHAOTPXVQNOHP-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenylpropylamines</td></tr><tr><th>Direct parent</th><td>Phenylpropylamines</td></tr><tr><th>Alternative parents</th><td>Fluorobenzenes; Aryl Fluorides; Triazoles; Tertiary Alcohols; Polyamines; Organofluorides</td></tr><tr><th>Substituents</th><td>fluorobenzene; aryl halide; aryl fluoride; azole; tertiary alcohol; 1,2,4-triazole; polyamine; organohalogen; organofluoride; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of fungal infections.</td></tr><tr><th>Pharmacodynamics</th><td>Fluconazole, a synthetic antifungal agent of the imidazole class, is used to treat vaginal candidiasis. It inhibits the fungal lanosterol 14 alpha-demethylase which thereby prevents the formation of ergosterol which is an essential component in the fungal cell membrane.</td></tr><tr><th>Mechanism of action</th><td>Fluconazole interacts with 14-&#945; demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Fluconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.</td></tr><tr><th>Absorption</th><td>90%</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>11 to 12%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p></td></tr><tr><th>Route of elimination</th><td>In normal volunteers, fluconazole is cleared primarily by renal excretion, with approximately 80% of the administered dose appearing in the urine as unchanged drug.</td></tr><tr><th>Half life</th><td>30 hours (range 20-50 hours)</td></tr><tr><th>Clearance</th><td><ul>
	<li>0.23 mL/min/Kg [adults]</li>
	<li>0.18 mL/min/Kg [In premature newborns within 36 hours of birth]</li>
	<li>0.22 mL/min/Kg [In premature newborns 6 days old]</li>
	<li>0.33 mL/min/Kg [In premature newborns 12 days old]</li>
	<li>0.4 mL/min/kg [9 Months-13 yearsreceiving single-oral 2 mg/kg]</li>
	<li>0.51 mL/min/Kg [9 Months-13 yearsreceiving single-oral 8 mg/kg]</li>
	<li>0.49 mL/min/Kg [5-15  yearsreceiving multiple IV 2 mg/kg]</li>
	<li>0.59 mL/min/Kg [5-15  yearsreceiving multiple IV 4 mg/kg]</li>
	<li>0.66 mL/min/Kg [5-15  yearsreceiving multiple IV 8 mg/kg]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include hallucinations and paranoid behavior.</td></tr><tr><th>Affected organisms</th><td><ul><li>Fungi</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9894</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6008</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8782</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9004</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6461</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.565</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6312</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5497</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.809</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.532</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8196</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.524</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.548
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7298
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4136 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8229
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6614
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pfizer chemicals div pfizer inc</li>
<li>Aurobindo pharma usa inc</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Ranbaxy laboratories ltd</li>
<li>Roxane laboratories inc</li>
<li>Taro pharmaceutical industries ltd</li>
<li>Pfizer inc</li>
<li>Acs dobfar info sa</li>
<li>Apotex inc richmond hill</li>
<li>Hospira inc</li>
<li>App pharmaceuticals llc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Claris lifesciences ltd</li>
<li>Hikma farmaceutica portugal lda</li>
<li>Teva parenteral medicines inc</li>
<li>Baxter healthcare corp</li>
<li>Bedford laboratories</li>
<li>Pfizer central research</li>
<li>Apotex inc</li>
<li>Aurobindo pharma ltd</li>
<li>Dr reddys laboratories inc</li>
<li>Gedeon richter usa inc</li>
<li>Genpharm inc</li>
<li>Glenmark generics ltd</li>
<li>Mylan pharmaceuticals inc</li>
<li>Pliva inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Unique pharmaceutical laboratories</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.aurobindo.com">Aurobindo Pharma Ltd.</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.cipla.com">Cipla Ltd.</a></li>
<li><a href="http://www.clarislifesciences.com">Claris Lifesciences Inc.</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Direct Pharmaceuticals Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li><a href="http://www.glenmark-generics.com">Glenmark Generics Ltd.</a></li>
<li><a href="http://www.greenstonellc.com">Greenstone LLC</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li><a href="http://www.haemonetics.com">Haemonetics Corp.</a></li>
<li><a href="http://www.hikma.com">Hikma Pharmaceuticals</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li>Ivax Pharmaceuticals</li>
<li><a href="http://www.jbcpl.com">J.B. Chemicals &amp; Pharmaceuticals</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Northstar Rx LLC</li>
<li>Novopharm Ltd.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Redpharm Drug</li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.sagentpharma.com">Sagent Pharmaceuticals</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.ziyuanpharm.com">Shanghai Ziyuan Pharmaceutical Co. Ltd.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Liquid</td><td>Intravenous</td><td></td></tr><tr><td>Powder, for solution</td><td>Oral</td><td></td></tr><tr><td>Solution</td><td>Intravenous</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Fluconazole may increase the serum concentration of acenocoumarol by decreasing its metabolism.</td></tr><tr><td><a href="/drugs/DB00802">Alfentanil</a></td><td>Increases the effect and toxicity of alfentanil</td></tr><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>Fluconazole may increase the effect of the benzodiazepine, alprazolam.</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Fluconazole may increase the serum concentration of anisindione by decreasing its metabolism.</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01558">Bromazepam</a></td><td>Fluconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if fluconazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Fluconazole may increase the therapeutic and adverse effects of carbamazepine.</td></tr><tr><td><a href="/drugs/DB00395">Carisoprodol</a></td><td>Strong CYP2C19 inhibitors such as fluconazole may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.</td></tr><tr><td><a href="/drugs/DB00482">Celecoxib</a></td><td>Fluconazole may increase the effect of celecoxib.</td></tr><tr><td><a href="/drugs/DB00475">Chlordiazepoxide</a></td><td>Fluconazole may increase the effect of the benzodiazepine, chlordiazepoxide.</td></tr><tr><td><a href="/drugs/DB01166">Cilostazol</a></td><td>Fluconazole may decrease the effect of cilostazol.</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01068">Clonazepam</a></td><td>Fluconazole may increase the effect of the benzodiazepine, clonazepam.</td></tr><tr><td><a href="/drugs/DB00628">Clorazepate</a></td><td>Fluconazole may increase the effect of the benzodiazepine, clorazepate.</td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated. </td></tr><tr><td><a href="/drugs/DB00531">Cyclophosphamide</a></td><td>Fluconazole reduces metabolism and clearance of cyclophosphamide.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Fluconazole may increase the therapeutic and adverse effects of the cyclosporine.</td></tr><tr><td><a href="/drugs/DB00829">Diazepam</a></td><td>Fluconazole may increase the effect of the benzodiazepine, diazepam.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Fluconazole may increase the serum concentration of dicumarol by decreasing its metabolism.</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB00700">Eplerenone</a></td><td>This CYP3A4 inhibitor increases the effect and toxicity of eplerenone</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB01215">Estazolam</a></td><td>Fluconazole may increase the effect of the benzodiazepine, estazolam.</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB01590">Everolimus</a></td><td>Fluconazole may increase everolimus levels/toxicity.</td></tr><tr><td><a href="/drugs/DB00813">Fentanyl</a></td><td>Fluconazole may increase levels/toxicity of fentanyl.</td></tr><tr><td><a href="/drugs/DB06702">Fesoterodine</a></td><td>Fluconazole is a moderate CYP3A4 inhibitor thus reducing clearance. Monitor for adverse effects when using concomitant therapy with fesoterodine. </td></tr><tr><td><a href="/drugs/DB00690">Flurazepam</a></td><td>Fluconazole may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB01095">Fluvastatin</a></td><td>Fluconazole may increase the serum concentration of fluvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fluvastatin if fluconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Fluconazole may increase the effect of hydantoin.</td></tr><tr><td><a href="/drugs/DB00801">Halazepam</a></td><td>Fluconazole may increase the effect of the benzodiazepine, halazepam.</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>Fluconazole may increase the effect and toxicity of haloperidol.</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of imipramine if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB08820">Ivacaftor</a></td><td>Moderate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction. </td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Increases the effect of hydantoin</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Fluconazole may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB04938">Ospemifene</a></td><td>Fluconazole, a moderate CYP3A / strong CYP2C9 / moderate CYP2C19 inhibitor, should not be used with ospemifene. Fluconazole increases the systemic exposure of ospemifene by 2.7-fold. Administration of fluconazole with ospemifene may increase the risk of adverse events. </td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Fluconazole may increase the therapeutic and adverse effects of phenytoin.</td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01589">Quazepam</a></td><td>Fluconazole may increase the effect of the benzodiazepine, quazepam.</td></tr><tr><td><a href="/drugs/DB00980">Ramelteon</a></td><td>Fluconazole may increase the serum levels and toxcity of ramelteon.</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Increased levels of ranolazine - risk of toxicity</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Fluconazole may increase levels/toxicity of rifabutin.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the effect of fluconazole.</td></tr><tr><td><a href="/drugs/DB06207">Silodosin</a></td><td>Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The antifungal, fluconazole, may also increase serum concentrations of tacrolimus.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Fluconzole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluconazole  is initiated, discontinued or dose changed.
</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Fluconzole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fluconazole is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Fluconazole may increase the serum concentration of Tipranavir. Dose adjustments are not required.</td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Fluconazole (and other strong CYP2C19 inhibitors and moderate CYP3A4 inhibitors), when used in combination with tofacitinib, may increase tofacitinib concentration. It is recommended to modify therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5mg daily. </td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Fluconazole therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Fluconazole may decrease the metabolism and clearance of tolterodine. Adjust tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB06212">Tolvaptan</a></td><td>Fluconazole is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations</td></tr><tr><td><a href="/drugs/DB00214">Torasemide</a></td><td>Fluconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Fluconazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Fluconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inhibitor, Fluconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fluconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>Fluconazole may increase the effect of the benzodiazepine, triazolam.</td></tr><tr><td><a href="/drugs/DB00440">Trimethoprim</a></td><td>The strong CYP2C9 inhibitor, Fluconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Fluconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Fluconazole, a strong CYP2C19 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00580">Valdecoxib</a></td><td>Fluconazole may increase the effect and toxicity of valdecoxib.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Fluconazole may increase the serum concentration of Verapamil by decreasing Verapamil metabolism. This likely occurs via Fluconazole-mediated CYP3A4 inhibition. Monitor for changes in the therapeutic/adverse effects of Verapamil if Fluconazole is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>Increases the effect and toxicity of anticancer agent</td></tr><tr><td><a href="/drugs/DB00541">Vincristine</a></td><td>Increases the effect and toxicity of anticancer agent</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Fluconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of voriconazole if fluconazole is initiated, discontinued or dose changed.	</td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00549">Zafirlukast</a></td><td>Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if fluconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00425">Zolpidem</a></td><td>Fluconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if fluconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>